Notable
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Primary completion pushed from May 31, 2024 to Mar 2027
Also in this update: Enrollment reopened; Study completion pushed from May 1, 2026 to Dec 2028
Bai-Rong XiaPhase 2 NCT05652283 Registry history of NCT05652283 on ClinicalTrials.gov (opens the registry)